Tempus AI, Inc. (TEM) Free Cash Flow Yield: N/A
The free cash flow yield for Tempus AI, Inc. (TEM) is N/A as of Friday, June 12, 2026.
TEM Free Cash Flow Yield Chart
TEM Average Free Cash Flow Yield Chart
TEM Free Cash Flow Yield Metrics
FREE CASH FLOW YIELD
N/A
FREE CASH FLOW YIELD AVG TTM
-3.09%
FREE CASH FLOW YIELD AVG 3Y
-3.23%
FREE CASH FLOW YIELD AVG 5Y
-3.23%
FREE CASH FLOW YIELD AVG 10Y
-3.07%
FREE CASH FLOW YIELD AVG 15Y
-3.07%
FREE CASH FLOW YIELD AVG 20Y
-3.07%
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
TEM Competitors' Free Cash Flow Yield
| NAME | MARKET CAP | FREE CASH FLOW YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Tempus AI, Inc. (TEM) | $8.65B | N/A | -3.09% | -3.23% | -3.23% |
| Charles River Laboratories International, Inc. (CRL) | $9.06B | 4.25% | 6.30% | 5.03% | 4.15% |
| Bio-Rad Laboratories, Inc. (BIO) | $7.91B | 4.53% | 4.53% | 3.11% | 2.79% |
| Baxter International Inc. (BAX) | $10.70B | 6.77% | 3.16% | 3.91% | 3.74% |
| Hims & Hers Health, Inc. (HIMS) | $6.44B | 1.15% | 1.43% | 1.61% | 1.61% |
| Align Technology, Inc. (ALGN) | $12.64B | 5.43% | 5.41% | 3.77% | 3.05% |
| Solventum Corporation (SOLV) | $13.72B | N/A | 2.46% | 7.43% | 7.43% |
| Hologic, Inc. (HOLX) | $16.97B | 5.82% | 6.30% | 5.70% | 7.89% |
| 23andMe Holding Co. (ME) | $15.31M | N/A | -496.25% | -255.12% | -171.49% |
| Moderna, Inc. (MRNA) | $19.70B | N/A | 8.49% | 9.09% | 9.09% |
Yield Comparison
FCF Yield
N/A
Earnings Yield
N/A
Dividend Yield
N/A
Formula: FCF Yield = (Free Cash Flow / Market Cap) × 100
How FCF Yield is used:
- Shows free cash flow after capital expenditures relative to market cap
- Can be compared with earnings yield and dividend yield
- Can be compared with the company's historical range
- Can be compared with peers that report positive free cash flow
FCF vs earnings: Differences between FCF yield and earnings yield can reflect capital expenditures, working capital changes, and other non-cash accounting items.
Tempus AI, Inc. Free Cash Flow Yield Formula & Definition
FCF Yield measures free cash flow relative to market capitalization. It compares cash generation after capital expenditures with the equity value of the company.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Tempus AI, Inc. Free Cash Flow Yield FAQ
- What is the free cash flow yield for Tempus AI, Inc. (TEM)?
- The free cash flow yield for TEM stock is N/A.
- What is the TTM average free cash flow yield for Tempus AI, Inc. (TEM)?
- The TTM average free cash flow yield for TEM stock is -3.09%.
- What is the 3Y average free cash flow yield for Tempus AI, Inc. (TEM)?
- The 3Y average free cash flow yield for TEM stock is -3.23%.
- What is the 5Y average free cash flow yield for Tempus AI, Inc. (TEM)?
- The 5Y average free cash flow yield for TEM stock is -3.23%.
- What is the 10Y average free cash flow yield for Tempus AI, Inc. (TEM)?
- The 10Y average free cash flow yield for TEM stock is -3.07%.
- What is the 15Y average free cash flow yield for Tempus AI, Inc. (TEM)?
- The 15Y average free cash flow yield for TEM stock is -3.07%.
- What is the 20Y average free cash flow yield for Tempus AI, Inc. (TEM)?
- The 20Y average free cash flow yield for TEM stock is -3.07%.
Tempus AI, Inc. Free Cash Flow Yield History
| DATE | FREE CASH FLOW YIELD |
|---|---|
| 2025-12-31 | -2.32% |
| 2024-12-31 | -3.86% |
| 2023-12-31 | -4.01% |
| 2022-12-31 | -2.73% |
| 2021-12-31 | -3.27% |
| 2020-12-31 | -3.22% |
| 2019-12-31 | -2.07% |
About Tempus AI, Inc.
Tempus AI, Inc. functions as a pioneering health technology enterprise. It specializes in delivering advanced diagnostic services, including cutting-edge genomic sequencing, PCR analysis, molecular genotyping, and various other anatomical and molecular pathology assessments. These vital services are provided to a diverse clientele, including medical practitioners, pharmaceutical companies, biotechnology innovators, scientific researchers, and other collaborating entities. The company offers "Insights," a licensed repository of de-identified clinical, molecular, and imaging data, complemented by a comprehensive suite of analytical and cloud-based computing services, primarily aimed at pharmaceutical and biotechnology firms. Additionally, its "Trials" program facilitates clinical trial matching services specifically for pharmaceutical companies. Tempus AI also manages several other platforms: "Next"; "Algos," a collection of algorithm-driven tests focused on oncology; "Hub," a versatile desktop and mobile application for ordering, managing, and receiving test results for patients; and "Lens," a dedicated portal enabling researchers and scientists to discover, access, and analyze the extensive Tempus dataset. Further demonstrating its commitment to innovation, Tempus AI has formed strategic alliances with AstraZeneca and Pathos AI, Inc. for the co-development of oncological therapeutic initiatives. Established in 2015, the company was initially known as Tempus Labs, Inc. before officially rebranding to Tempus AI, Inc. in January 2023. Its operations are based out of Chicago, Illinois.
- Sector
- Healthcare
- Industry
- Medical - Healthcare Information Services
- CEO
- Eric Lefkofsky